DSSG Group: Sarcoma

To be eligible for this study, patients must meet several requirements, including:

Participants must have inoperable or metastatic chondrosarcoma that is continuing to grow.
At least 4 weeks must pass between the completion of any prior treatments and receipt of the study medication.
Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
This study is for people age 18 and older.

The purpose of this study is to assess the safety and effectiveness of the investigational drug INBRX-109 to treat people with chondrosarcoma that cannot be surgically removed or has spread to other parts of the body. INBRX-109 targets a type of protein found on cancer cells. When it binds to these proteins, the cancer cells die.

Participants will be randomly assigned to receive INBRX-109 or a placebo (inactive drug). Patients who receive the placebo will have the opportunity to receive INBRX-109 if their cancer grows. INBRX-109 is given intravenously (by vein).